AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38551617 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided digital mental health intervention (Happify for Teens) for 12 weeks
Number of subjects: 303
Study 38551617 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control for 12 weeks
Number of subjects: 303
Study 38551689 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic burden (ACB)
Number of subjects: 636
Study 38551689 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy (PP)
Number of subjects: 636
Study 38551689 — intervention group
Group type: EXPERIMENTAL
Intervention: Potential drug-drug interactions (DDIs)
Number of subjects: 636
Study 38551689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative anticholinergic burden (ACB)
Number of subjects: 636
Study 38551773 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise interventions (specific types not detailed), duration: 6 months
Number of subjects: 0
Study 38551773 — intervention group
Group type: COMPARATOR
Intervention: High-functioning group with low symptoms
Number of subjects: 0
Study 38551773 — intervention group
Group type: EXPERIMENTAL
Intervention: Various algorithms (Random Forest, Logistic Regression, Ridge Regression)
Number of subjects: 0
Study 38551807 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO)
Number of subjects: 43
Study 38551806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 13
Study 38551926 — intervention group
Group type: EXPERIMENTAL
Intervention: Stunted children
Number of subjects: 200
Study 38551926 — intervention group
Group type: COMPARATOR
Intervention: Non-stunted children
Number of subjects: 200
Study 38551934 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal angioplasty (PTA/stenting) in TRAS group (N = 20)
Number of subjects: 34
Study 38551934 — intervention group
Group type: COMPARATOR
Intervention: Clinical treatment in TNS group (N = 14)
Number of subjects: 34
Study 38551973 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-field magnification display
Number of subjects: 88
Study 38551973 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual bioptic telescope mode
Number of subjects: 88
Study 38551981 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme in everyday cognition
Number of subjects: 0
Study 38551981 — intervention group
Group type: COMPARATOR
Intervention: Traditional cognitive stimulation
Number of subjects: 0
Study 38551983 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral thiamine (600-1800 mg daily) for 4 weeks
Number of subjects: 36
Study 38551983 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 4 weeks
Number of subjects: 36
Study 38552177 — intervention group
Group type: EXPERIMENTAL
Intervention: Superior approach (SA)
Number of subjects: 119
Study 38552177 — intervention group
Group type: COMPARATOR
Intervention: Conventional femoral approach (FA)
Number of subjects: 119
Study 38552188 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I), 7 weekly virtual sessions
Number of subjects: 132
Study 38552188 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 132
Study 38552197 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1,200 mg intravenously once every 3 weeks plus cabozantinib 40 mg orally once daily
Number of subjects: 366
Study 38552197 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel 75 mg/m2
Number of subjects: 366
Study 38552208 — intervention group
Group type: EXPERIMENTAL
Intervention: Remdesivir plus standard of care (SoC)
Number of subjects: 833
Study 38552208 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SoC) alone
Number of subjects: 833
Study 38552315 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tocilizumab (SC-TCZ) treatment
Number of subjects: 82
Study 38552323 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial and Insurance Navigation Assistance (financial navigation)
Number of subjects: 45
Study 38552429 — intervention group
Group type: EXPERIMENTAL
Intervention: Baha SoundArc
Number of subjects: 25
Study 38552429 — intervention group
Group type: COMPARATOR
Intervention: Baha Softband
Number of subjects: 25
Study 38552629 — intervention group
Group type: EXPERIMENTAL
Intervention: Icosapent ethyl (IPE) 4 g/day
Number of subjects: 70
Study 38552629 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 38552653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination at 1 year (group 1)
Number of subjects: 699
Study 38552653 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV booster vaccination at 2 years (group 2)
Number of subjects: 699
Study 38552653 — intervention group
Group type: COMPARATOR
Intervention: Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
Number of subjects: 699
Study 38552656 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilogy transcatheter heart valve (TAVI)
Number of subjects: 180
Study 38552659 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose group (10 mg/kg once daily for 4 months)
Number of subjects: 1368
Study 38552659 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/kg group (20 mg/kg daily for 2 months)
Number of subjects: 1368
Study 38552659 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg group (30 mg/kg daily for 2 months)
Number of subjects: 1368
Study 38553053 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTing Minds video game intervention
Number of subjects: 36
Study 38553055 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care tests (POCTs) including phase-contrast microscopy and urinary dipsticks for detecting bacteria and erythrocytes in urine samples.
Number of subjects: 20
Study 38553055 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 20
Study 38553057 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 24
Study 38553057 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental strategies
Number of subjects: 24
Study 38553057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined (financial incentives and environmental strategies)
Number of subjects: 24
Study 38553057 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 24
Study 38553062 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised prehabilitation programme including coached, supervised or self-directed physical activity and weekly dietary follow-up.
Number of subjects: 50
Study 38553291 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text message invitation strategy with pre-alert message
Number of subjects: 88820
Study 38553291 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural science-informed text message invitation strategy without pre-alert message
Number of subjects: 88820
Study 38553291 — intervention group
Group type: COMPARATOR
Intervention: Control (current practice) text message
Number of subjects: 88820
Study 38553461 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific T cells (VST) from partially-HLA matched donors
Number of subjects: 1
Study 38553525 — intervention group
Group type: EXPERIMENTAL
Intervention: cAd3-EBOZ or cAd3-EBO prime followed by MVA-EbolaZ boost
Number of subjects: 230
Study 38553594 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (NCRT) followed by neoadjuvant consolidation chemotherapy (NCCT)
Number of subjects: 46
Study 38553602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier
Number of subjects: 60
Study 38553602 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacifier with 25% dextrose
Number of subjects: 60
Study 38553602 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 38553649 — intervention group
Group type: EXPERIMENTAL
Intervention: WFPB dietary intervention
Number of subjects: 31
Study 38553649 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study 38553674 — intervention group
Group type: EXPERIMENTAL
Intervention: Handmade ultrasound-guided phantom for paracentesis training
Number of subjects: 50
Study 38553680 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX (12 cycles every 2 weeks)
Number of subjects: 312
Study 38553680 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX 6 (12 cycles every 2 weeks)
Number of subjects: 312
Study 38553680 — intervention group
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Number of subjects: 312
Study 38553680 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX 6
Number of subjects: 312
Study 38553690 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (NW) training combined with 10 hours' time-restricted eating (TRE) for 12 weeks
Number of subjects: 24
Study 38553746 — intervention group
Group type: EXPERIMENTAL
Intervention: Device feedback only
Number of subjects: 0
Study 38553746 — intervention group
Group type: EXPERIMENTAL
Intervention: Device feedback plus parent communication training
Number of subjects: 0
Study 38553746 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 38553749 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU survivors
Number of subjects: 590
Study 38553749 — intervention group
Group type: COMPARATOR
Intervention: Non-ICU-treated controls
Number of subjects: 590
Study 38553950 — intervention group
Group type: EXPERIMENTAL
Intervention: WES/RNA-Seq
Number of subjects: 50
Study 38553950 — intervention group
Group type: COMPARATOR
Intervention: TGP/aCGH
Number of subjects: 50
Study 38553990 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative DOTATATE PET/MRI
Number of subjects: 27
Study 38554013 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week online fall prevention intervention (weekly virtual group discussions, individual phone check-ins, home exercises)
Number of subjects: 43
Study 38554013 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 43
Study 38554156 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezabenlimab 240 mg
Number of subjects: 117
Study 38554232 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg once daily (QD)
Number of subjects: 0
Study 38554232 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg QD
Number of subjects: 0
Study 38554563 — intervention group
Group type: EXPERIMENTAL
Intervention: Single IV R-KET administration
Number of subjects: 3
Study 38554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical Bacillus Calmette-Guérin (BCG) combined with intravenous pembrolizumab
Number of subjects: 18
Study 38554618 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief video intervention
Number of subjects: 1405
Study 38554618 — intervention group
Group type: COMPARATOR
Intervention: Control video
Number of subjects: 1405
Study 38554717 — intervention group
Group type: EXPERIMENTAL
Intervention: sintilimab (200 mg on day 1) plus P-GEMOX (pegaspargase 2000 U/m2, gemcitabine, and oxaliplatin)
Number of subjects: 34
Study 38554715 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 130
Study 38554715 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 38554726 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal injection of RGX-314 (dose range 3 × 10)
Number of subjects: 68
Study 38554726 — intervention group
Group type: EXPERIMENTAL
Intervention: Subretinal injection of RGX-314
Number of subjects: 68
Study 38554725 — intervention group
Group type: EXPERIMENTAL
Intervention: Afamitresgene autoleucel (afami-cel), single intravenous dose (transduced dose range 1·0 × 10)
Number of subjects: 52
Study 38554725 — intervention group
Group type: EXPERIMENTAL
Intervention: Afamitresgene autoleucel (afami-cel)
Number of subjects: 52
Study 38554817 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-assisted Abrams needle pleural biopsy (IA-ANPB) in Group 1
Number of subjects: 228
Study 38554817 — intervention group
Group type: COMPARATOR
Intervention: Medical Thoracoscopy (MT) in Group 1
Number of subjects: 228
Study 38554817 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-assisted Abrams needle pleural biopsy (IA-ANPB) in Group 2
Number of subjects: 228
Study 38554817 — intervention group
Group type: COMPARATOR
Intervention: Medical Thoracoscopy (MT) in Group 2
Number of subjects: 228
Study 38554817 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications rate for IA-ANPB
Number of subjects: 228
Study 38554817 — intervention group
Group type: COMPARATOR
Intervention: Complications rate for MT
Number of subjects: 228
Study 38554938 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg
Number of subjects: 171
Study 38554938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 38555057 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid-filled pressure guidewires
Number of subjects: 50
Study 38555057 — intervention group
Group type: COMPARATOR
Intervention: Sensor-tipped pressure guidewires
Number of subjects: 50
Study 38555079 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 1902
Study 38555079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1902
Study 38555240 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning model using Extreme Gradient Boost algorithm
Number of subjects: 6282
Study 38555253 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NPY levels above median (70 pg/ml)
Number of subjects: 260
Study 38555253 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma NPY levels above median (70 pg/ml) after 4 months
Number of subjects: 260
Study 38555285 — intervention group
Group type: EXPERIMENTAL
Intervention: CHK1 inhibitor prexasertib (CHK1i) in cohort 5
Number of subjects: 49
Study 38555285 — intervention group
Group type: EXPERIMENTAL
Intervention: CHK1 inhibitor prexasertib (CHK1i) in cohort 6
Number of subjects: 49
Study 38555307 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-trail race (156-km)
Number of subjects: 55
Study 38555307 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-race period (48-h)
Number of subjects: 55
Study 38555311 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib, lenalidomide and rituximab (R2A)
Number of subjects: 66
Study 38555336 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Frailty Scale (CFS)
Number of subjects: 3920
Study 38555336 — intervention group
Group type: EXPERIMENTAL
Intervention: Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE)
Number of subjects: 3920
Study 38555336 — intervention group
Group type: EXPERIMENTAL
Intervention: Katz activities of daily living (ADL) score
Number of subjects: 3920
Study 38555336 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-month mortality
Number of subjects: 3920
Study 38555336 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and frailty
Number of subjects: 3920
Study 38555417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-trained model mn30_as
Number of subjects: 198
Study 38555417 — intervention group
Group type: EXPERIMENTAL
Intervention: Male model mn30_as
Number of subjects: 198
Study 38555417 — intervention group
Group type: EXPERIMENTAL
Intervention: Female model mn30_as
Number of subjects: 198
Study 38555417 — intervention group
Group type: EXPERIMENTAL
Intervention: Female model mn4.0
Number of subjects: 198
Study 38555417 — intervention group
Group type: EXPERIMENTAL
Intervention: Other models (pre-trained; mn40_as, non-pre-trained; mn4.0 and mn3.0)
Number of subjects: 198
Study 38555718 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (1.5-2 mg/kg/day orally for 6 weeks)
Number of subjects: 108
Study 38555718 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (375 mg/m2)
Number of subjects: 108
Study 38555865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified cooperation between GP, care manager, and rehabilitation coordinator plus a person-centred dialogue meeting with employer within 3 months.
Number of subjects: 258
Study 38555865 — intervention group
Group type: COMPARATOR
Intervention: Usual care manager contact (control group).
Number of subjects: 258
Study 38555865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified cooperation and dialogue meeting (intervention group).
Number of subjects: 258
Study 38555923 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD30 CAR T-cell infusion
Number of subjects: 21
Study 38556413 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypofractionated radiotherapy combined with a radiosensitizer (intravenous or oral drug) administered 5 days a week for 4 weeks.
Number of subjects: 0
Study 38556413 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate hypofractionated radiotherapy combined with a radiosensitizer (intravenous or oral drug).
Number of subjects: 0
Study 38556640 — intervention group
Group type: EXPERIMENTAL
Intervention: Water Therapy
Number of subjects: 0
Study 38556640 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 38556717 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct sodium removal (DSR) with loop diuretic withdrawal; median time of DSR 4 weeks (IQR 4-6); baseline median 240 mg furosemide equivalents/day withdrawn during DSR.
Number of subjects: 18
Study 38557264 — intervention group
Group type: EXPERIMENTAL
Intervention: Short Physical Performance Battery (SPPB)
Number of subjects: 45
Study 38557285 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Number of subjects: 34
Study 38557315 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-based risk prediction system for graft loss, starting from 3 months after randomization until 24 months after randomization.
Number of subjects: 122
Study 38557315 — intervention group
Group type: COMPARATOR
Intervention: Routine post-kidney transplant care (control group).
Number of subjects: 122
Study 38557430 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray (ESK) plus newly initiated oral antidepressant (OAD)
Number of subjects: 0
Study 38557430 — intervention group
Group type: COMPARATOR
Intervention: Oral antidepressant (OAD) plus placebo nasal spray (PBO)
Number of subjects: 0
Study 38557591 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital educational intervention focusing on front-of-package warning labels
Number of subjects: 0
Study 38557591 — intervention group
Group type: COMPARATOR
Intervention: General nutritional education (Control)
Number of subjects: 0
Study 38557591 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidance on reading labels and awareness about ultraprocessed products (Intervention)
Number of subjects: 0
Study 38557591 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-question exam to evaluate theoretical understanding
Number of subjects: 0
Study 38557591 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour reminder, survey on food habits and consumption, food preference scale, anthropometric measurements, recording of school lunch choices
Number of subjects: 0
Study 38557639 — intervention group
Group type: EXPERIMENTAL
Intervention: H56:IC31 (5 mg H56:500 nmol IC31)
Number of subjects: 22
Study 38557639 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 38557684 — intervention group
Group type: EXPERIMENTAL
Intervention: GCS-EM (sum of eye and motor components of the Glasgow Coma Score)
Number of subjects: 1152
Study 38557684 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses with different adjustment covariates
Number of subjects: 1152
Study 38557684 — intervention group
Group type: EXPERIMENTAL
Intervention: Subgroup analyses by brain injury diagnosis or age
Number of subjects: 1152
Study 38557692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile WACh Empower intervention (tablet-based RH decision-support counseling tool and SMS support during two years of follow-up)
Number of subjects: 3300
Study 38557692 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile WACh Empower intervention
Number of subjects: 3300
Study 38557692 — intervention group
Group type: COMPARATOR
Intervention: Standard of care FP counseling (control group)
Number of subjects: 3300
Study 38557775 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel; autologous anti-CD19 chimeric antigen receptor T-cell therapy)
Number of subjects: 0
Study 38557775 — intervention group
Group type: COMPARATOR
Intervention: Standard care (2-3 cycles of chemoimmunotherapy followed by high-dose chemotherapy with autologous stem cell transplantation in patients who had a response)
Number of subjects: 0
Study 38557775 — intervention group
Group type: EXPERIMENTAL
Intervention: Axicabtagene ciloleucel (axi-cel)
Number of subjects: 0
Study 38557775 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 38557809 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-BTN3A activation
Number of subjects: 0
Study 38557809 — intervention group
Group type: COMPARATOR
Intervention: SARS-CoV-2 infection
Number of subjects: 0
Study 38557809 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing concentrations of anti-BTN3A
Number of subjects: 0
Study 38557809 — intervention group
Group type: EXPERIMENTAL
Intervention: Vγ9Vδ2 T cells
Number of subjects: 0
Study 38557809 — intervention group
Group type: EXPERIMENTAL
Intervention: BTN3A upregulation and Vγ9Vδ2 T-cell infiltration
Number of subjects: 0
Study 38557877 — intervention group
Group type: EXPERIMENTAL
Intervention: HSP-SNAP questionnaire
Number of subjects: 40
Study 38557950 — intervention group
Group type: EXPERIMENTAL
Intervention: Regenerative Peripheral Nerve Interface (RPNI)
Number of subjects: 0
Study 38557950 — intervention group
Group type: COMPARATOR
Intervention: Targeted Muscle Reinnervation (TMR)
Number of subjects: 0
Study 38557950 — intervention group
Group type: COMPARATOR
Intervention: Neuroma excision coupled with intra-muscular transposition and burying
Number of subjects: 0
Study 38557959 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (TD group)
Number of subjects: 468
Study 38557959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (TD group)
Number of subjects: 468
Study 38557959 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine (HD group)
Number of subjects: 468
Study 38557959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (HD group)
Number of subjects: 468
Study 38558106 — intervention group
Group type: EXPERIMENTAL
Intervention: B-cell-targeted CAR T-cell therapy (tisagenlecleucel infusion)
Number of subjects: 0
Study 38558106 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2) and IL-15 exposure
Number of subjects: 0